Solid Biosciences CEO Bo Cumo discusses recent DMD data for the company's microdystrophin gene therapy, and explains the development and regulatory steps ahead

He describes data presented at the Muscular Dystophy Association Annual Meeting which showed biopsy and safety data for 20 patients who have been followed for 90 days and 3 who are out to a year. Plus, explaining the three FDA meetings that are key ffor the company.